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Topics discussed on HTA 
• Recent international guidelines 
• Importance of the quality of BP measurements 
• Role of Salt restriction for BP and CV risk management 
• Recent antihypertensive trials to test the new BP targets 
• Special clinical situations: 
    - BP target in CKD 
    - Resistant HTA 
    - Atherosclerotic RAS 





Summary of 2013 ESH guidelines   
• Stimulation of out of the office BP measurements  
• No initiation of drug anti HTA when high normal BP  
• Simplification and less strict BP targets 
• Delay before starting antiHTA treatment in the very old 
(>80y) and higher BP target than before 




When proposing out of the office measurement? 
Home BP 
• WCHTA 
• Masked HTA 
• Pregnancy induced HTA 
• Highly variable office BP  
• Resistant HTA 
ABPM 
• Dipping 
• Discordance office and 
home BP values 
• Variability approach 
 








When starting the treatment in HTA? 
ESH guidelines 2013 
ESH−ESC and JNC 7 Summary: Target BP Goals 
(2003 and 2007) 
Type of hypertension BP goal (mmHg) 
Uncomplicated  <140/90 
Complicated 
Diabetes mellitus <130/80 
Kidney disease <130/80 
Other high risk (stroke, myocardial 
infarction) 
<130/80 
Task Force of ESH–ESC. J Hypertens 2007;25:1105−87 
Chobanian et al. JAMA 2003;289:2560−72 
*Lower if proteinuria is >1 g/day 
New BP targets 
• SBP < 140/90 mmHg in all adults  < 80 ans (with or 
without CV complications) 
• In people older than 80 ans and in good health:  start 
antiHTA drugs when SBP> 160 mmHg with a BP target 
between 140 and 150 mmHg. 
• In Diabetes, target <140/85 mmHg 





• Systolic and Diastolic BP have different 
influences on the CV system 
• HTA carries a substantial lifetime burden 
despite treatment, with a 5y earlier 
development of CV than those with normal BP 
• There was no J-shaped increased risk for CV 





Blood pressure and mortality/ESRD risk 
Sim et al JACC 2014 
• Obervational retrospective study in treated HT 
• U-shaped curve for mortality/ESRD at SBP either 
>139 mmHg or <130 mmHg  
• Ideal BP 137/71. 
• DBP <60 and >79 had similar greater risk. 
• So it is recommended to adapt antiHTA drugs to 
reach these targets 
• DM has a lower nadir for mortality/ESRD risk : 
131/69 mmHg 




HTA in special situations 
• CKD 
• Resistance 
• Atherosclerotic stenosis 
• Hemodialysis 






Renal denervation in  
Resistant HTA ? 
• Among 30000 people followed in USA, 14800 are taking 
antiHTA drugs 
• 78 (0.5%) are refractory to 5 or more antiHTA agents 
• 2066 (14%) are considered resistant (normalisation of 
BP with more than 3 drugs) 
• Refractory people are mainly men, black, obese, 
diabetic, suffering from proteinuria, CKD, or having an 






Should we still consider renal 
denervation for Resistant HTA? 
• Interests in glucose metabolism, LVH, CHF, AF, 












• Small decrease in DBP and number of antiHTA agents in 
the stenting group according to 7 RCT studies (2155 
patients at baseline and 1741 available at FU) 
• No difference in SBP, serum creatinine, incident CV 
event rates 
• However, the patients included are those whose the 
baseline therapeutic decision was uncertain (low risk 
group) 











Take home messages (1)  
• HTA is a CV risk factor which should be treated. A 
good definition is required (out of the office 
measurement). The lower the better is no more 
proposed. 
• The ideal BP target is <140/90 mmHg for the 
majority < 80. Be less aggressive in people >80. 
• Going lower than 120 mmHg for the SBP could be 
deleterious.  
• Salt restriction sems useful but should not be too 
strict with stimulation of increasing K intake. 
Take home messages (2) 
• In CKD patients, the BP target is not different than in 
general HT population. 
• In Resistant HTA, RDN is at the present time no more 
recommanded. 
• In RAS due to atherosclerosis, encourage the medical 
treatment first. Angioplasty is to be reserved for a 
minority who must be identified. 
• In HD population, interest of atenolol and 
spironolactone? 
 
 
Thank you 
 
 
Any questions? 

